Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H1N1 Vaccine Dose-Ranging Study in Children
NCT00971542Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2009
- Primary completion
- Feb 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 5
01
Overview
Phase 3, randomised, single-blind trial of Influenza A (H1N1) vaccine in influenza A H1N1 infection (H1N1) (3 arms), sponsored by Novartis. Primary endpoint: Preferred vaccine formulation dosage (antigen & adjuvant) and schedule at 43 days. Started Sep 2009; status: completed.
02
Drugs
Influenza A (H1N1) vaccine
03
Conditions
influenza A H1N1 infection (H1N1)
Beyond the preview
Go deeper on NCT00971542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00971542.